Chromogranin-A as a serum marker for neuroendocrine tumors: comparison with neuron-specific enolase and correlation with immunohistochemical findings.

Détails

ID Serval
serval:BIB_801FE9742F0C
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Chromogranin-A as a serum marker for neuroendocrine tumors: comparison with neuron-specific enolase and correlation with immunohistochemical findings.
Périodique
International Journal of Biological Markers
Auteur(s)
Giovanella L., La Rosa S., Ceriani L., Uccella S., Erba P., Garancini S.
ISSN
0393-6155 (Print)
ISSN-L
0393-6155
Statut éditorial
Publié
Date de publication
1999
Peer-reviewed
Oui
Volume
14
Numéro
3
Pages
160-166
Langue
anglais
Notes
Publication types: Comparative Study ; Journal ArticlePublication Status: ppublish
Résumé
BACKGROUND: Chromogranin-A (Cg-A) is a 439-amino-acid protein contained in secretory granules of neuroendocrine cells, in addition to specific hormone peptides or neuropeptides. Since Cg-A is co-released with peptide hormones its serum concentration can be used as a marker of neuroendocrine tumors.
AIM: Evaluation of the analytical performance of a new IRMA method for Cg-A assay and of the clinical value of serum Cg-A and neuron-specific enolase (NSE) in neuroendocrine tumors. In addition, we compared the diagnostic usefulness of both Cg-A and NSE serum levels and their relationship to tissue expression.
PATIENTS AND METHODS: Initially we evaluated the analytical performance (intra- and interassay imprecision, dilution test and detection limit) of the Cg-A RIACT method (CIS Bio-International, Gif-sur-Yvette, France). We selected 50 patients affected by various histologically confirmed neuroendocrine tumors (NETs): 111In-pentetreotide scan and helical computed tomography were employed to assess tumor extent. Cg-A and NSE were measured before surgery in serum samples of patients and 50 age-matched controls by IRMA methods. After surgery immunohistochemical stains for Cg-A and NSE were performed on surgical specimens of tumor tissue.
RESULTS: Cg-A levels were significantly higher (p < 0.0001) in patients with NETs than in healthy controls and we found a positive correlation between serum and tissue expression (p < 0.05). Serum levels of Cg-A were also related to tumor extent (p < 0.05) but in some cases we observed significant elevation of serum Cg-A in small, intensely immunoreactive NETs. ROC curve analysis showed better accuracy for serum Cg-A compared to NSE in the diagnosis of NETs, while no significant relationship was found between serum expression and immunostaining for NSE.
DISCUSSION: Our results confirmed the biological and clinical significance of circulating Cg-A as an expression of granular content in neuroendocrine tissues and supported the complementary usefulness of serum Cg-A in the diagnosis and evaluation of NETs together with imaging modalities.
Mots-clé
Adult, Aged, Aged, 80 and over, Biomarkers, Tumor/blood, Chromogranin A, Chromogranins/blood, Female, Humans, Immunohistochemistry, Male, Middle Aged, Neuroendocrine Tumors/diagnosis, Phosphopyruvate Hydratase/blood
Pubmed
Web of science
Création de la notice
07/09/2016 8:37
Dernière modification de la notice
20/08/2019 14:40
Données d'usage